График акции Pulse Biosciences, Inc.
Расширенный график
Простой график
О компании
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. The company was incorporated in 2014 and is headquartered in Hayward, California.
| EBITDA |
-0.0468 |
| EV/EBITDA |
-6.25 |
| IPO date |
2016-05-18 |
| ISIN |
US74587B1017 |
| Industry |
Health Care Equipment & Supplies |
| P/BV |
9.52 |
| P/S |
4865.77 |
| Sector |
Health Care |
| Валюта |
usd |
| Валюта отчета |
usd |
| Выручка |
0.000114 |
| Сайт |
https://www.pulsebiosciences.com
|
| Цена ао |
8.25 |
| Число акций ао |
0.04804 млрд |
| Изменение цены за день: |
+3.79% (16.1) |
| Изменение цены за неделю: |
-2.88% (17.205) |
| Изменение цены за месяц: |
-4.41% (17.48) |
| Изменение цены за 3 месяца: |
+7.74% (15.51) |
| Изменение цены за полгода: |
+121.91% (7.53) |
| Изменение цены за год: |
+285.91% (4.33) |
| Изменение цены за 3 года: |
-24.08% (22.01) |
| Изменение цены за 5 лет: |
+41.37% (11.82) |
| Изменение цены за 10 лет: |
0% (16.71) |
| Изменение цены с начала года: |
+288.6% (4.3) |
|
|
Недооценка
| Название |
Значение |
Оценка |
| P/S |
-67573.45 |
0 |
| P/BV |
13.71 |
1 |
| P/E |
0 |
0 |
| EV/EBITDA |
-13.52 |
0 |
| Итого: |
|
1.88 |
|
Эффективность
| Название |
Значение |
Оценка |
| ROA, % |
-69.42 |
0 |
| ROE, % |
-95.15 |
0 |
| Итого: |
|
3.33 |
|
|
|
Дивиденды
| Название |
Значение |
Оценка |
| Div yield, % |
0 |
0 |
| DSI |
0 |
0 |
| Итого: |
|
0 |
|
Долг
| Название |
Значение |
Оценка |
| Debt/EBITDA |
-0.2158 |
10 |
| Итого: |
|
9.8 |
|
Импульс роста
| Название |
Значение |
Оценка |
| Доходность Revenue, % |
-103.64 |
0 |
| Доходность Ebitda, % |
-9.47 |
0 |
| Доходность EPS, % |
-60.42 |
0 |
| Итого: |
|
0 |
|
| Руководитель |
Должность |
Оплата |
Год рождения |
| Mr. Robert W. Duggan |
Executive Co-Chairman |
N/A |
1944 (80 лет) |
| Mr. Darrin R. Uecker |
CTO & Director |
834.73k |
1966 (58 лет) |
| Mr. Mitchell E. Levinson |
Chief Strategy Officer |
584.57k |
1960 (64 года) |
| Dr. Richard Nuccitelli Ph.D. |
Chief Science Officer |
N/A |
|
| Mr. Kenneth B. Stratton Esq., J.D. |
General Counsel & Corporate Secretary |
N/A |
1969 (55 лет) |
| Ms. Patty Perla |
Vice President of Human Resources |
N/A |
|
| Mr. David Danitz |
Senior Vice President of Engineering |
N/A |
|
| Mr. Kevin P. Danahy |
Chief Commercial Officer |
|
1971 (53 года) |
| Mr. Burke T. Barrett |
President, CEO & Director |
|
1964 (60 лет) |
| Mr. Edison Manuel |
Vice President of Operations |
|
|
